文献速递心律失常血脂与心血管预防

房颤患者使用非维生素K拮抗剂口服抗凝药预防卒中的年龄阈值:对年龄和偶发合并症最佳评估的见解

Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
PubMed 文献 · Eur Heart J · 2019-01-01

理想方法显示,使用NOACs的年龄阈值因单一风险因素而异:心衰35岁、高血压或糖尿病50岁、血管疾病55岁,传统方法高估卒中风险。

要点

  • 房颤卒中风险随年龄和偶发合并症动态变化,理想评估应考虑偶发合并症和卒中实际年龄。
  • 使用NOACs的年龄阈值:心衰35岁,高血压或糖尿病50岁,血管疾病55岁。
  • 传统方法高估卒中风险, incidence rate ratio为高血压1.24、心衰1.20、糖尿病1.37、血管疾病1.38(均P<0.01)。

核心结论

  • 房颤患者缺血性卒中风险异质,年龄是重要驱动因素。
  • 尽管CHA2DS2-VASc评分相同(男性1分,女性2分),不同单一风险因素的NOACs年龄阈值不同:心衰35岁、高血压或糖尿病50岁、血管疾病55岁。

研究设计与样本

  • 采用三种方法分析各年龄层各合并症的缺血性卒中风险:传统方法(基于基线风险因素和年龄)、动态方法(发生新合并症时删失)、理想方法(发生新合并症时删失且卒中风险与实际发生卒中时的年龄相关)。

主要发现

  • 传统方法评估的总体缺血性卒中风险高于动态或理想评估, incidence rate ratio为高血压1.24、心衰1.20、糖尿病1.37、血管疾病1.38,所有P值<0.01。
  • 各年龄层的缺血性卒中风险,传统或动态方法普遍高于理想评估。
  • 心衰患者的NOACs tipping point(年龄35岁)在不同评估方法间相似。
  • 根据理想评估结果,高血压、糖尿病和血管疾病患者使用NOACs的年龄阈值分别为50岁、50岁和55岁。

关键数值与推荐

  • NOACs使用的tipping point设定为卒中风险0.9%/年。
  • 理想评估下,心衰患者年龄阈值35岁,高血压或糖尿病患者50岁,血管疾病患者55岁。

临床怎么用

  • 临床决策中使用NOACs预防房颤卒中时,应考虑患者具体合并症类型及年龄,而非仅依赖CHA2DS2-VASc评分。
  • 对于心衰患者,NOACs年龄阈值可低至35岁;高血压或糖尿病为50岁;血管疾病为55岁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The stroke risk of patients with atrial fibrillation (AF) is not static, since AF patients get older and accumulate more comorbidities after AF is diagnosed. Therefore, the stroke risk of AF patients given certain comorbidities in different age strata should ideally be analysed using an assessment which considers incident comorbidities and the actual age when ischaemic stroke occurred. The goal of the present study is to report the age treatment thresholds for the use of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients without or with only one comorbidity of the CHA2DS2-VASc score, based on an 'ideal method' of stroke risk assessments. METHODS AND RESULTS: The study cohort included 31 039 and 39 020 AF patients who did not have any or had only one risk factor comorbidity of the CHA2DS2-VASc score except for age and sex. The risks of ischaemic stroke in each age strata for each comorbidities were analysed in three ways, as follows: (i) the conventional way (based on baseline risk factors and age), (ii) dynamic method (patients were censored when new comorbidities occurred), and (iii) an ideal method (patients were censored when new comorbidities occurred and the stroke risk was related to the actual age when stroke happened). The tipping point for the use of NOACs was set at a stroke risk of 0.9%/year. The overall risk of ischaemic stroke using the conventional way was overestimated compared to the dynamic or ideal assessment with the incidence rate ratio of 1.24 for patients with hypertension, 1.20 for heart failure, 1.37 for diabetes mellitus, and 1.38 for vascular diseases; all P-values <0.01. The risk of ischaemic stroke for each age strata was generally higher with the conventional or dynamic methods compared with the ideal assessment. With heart failure, the tipping point (age 35 years) of NOACs was similar, irrespective of methods used for stroke risk assessment. According to the results of ideal assessment, the age thresholds for the use of NOACs for patients with hypertension, diabetes mellitus, and vascular diseases were 50 years, 50 years, and 55 years, respectively. CONCLUSION: Ischaemic stroke risk in AF is heterogeneous, depending on different risk factors with age being as an important driver of stroke risk. Age thresholds for the use of NOACs were different for AF patients having different single risk factors beyond sex despite the same CHA2DS2-VASc score point (1 for males and 2 for females); that is, 35 years for heart failure, 50 years for hypertension or diabetes, and 55 years for vascular diseases.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chao TF, Lip GYH, Lin YJ, et al. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. Eur Heart J. 2019. PMID: 30605505. doi:10.1093/eurheartj/ehy837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。